Rajesh Panigrahi
Overview
Explore the profile of Rajesh Panigrahi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmadi E, Ravanshad M, Xie J, Panigrahi R, Jubbal S, Guru S, et al.
Virol J
. 2021 Nov;
18(1):223.
PMID: 34794463
Background: B-cell proliferative disorders, such as post-transplant lymphoproliferative disease (PTLD), are increased among persons afflicted by T-cell compromise. Most are Epstein-Barr virus (EBV) + and can first present with a...
2.
Aydin Y, Stephens C, Chava S, Heidari Z, Panigrahi R, Williams D, et al.
Am J Pathol
. 2018 Aug;
188(10):2339-2355.
PMID: 30075149
Liver cirrhosis is an independent risk factor for hepatocellular carcinoma (HCC). The mechanisms that contribute to HCC development in the cirrhotic microenvironment are unknown. We found that HCC grown in...
3.
Bandopadhyay M, Sarkar N, Datta S, Das D, Pal A, Panigrahi R, et al.
Infect Agent Cancer
. 2016 Aug;
11:40.
PMID: 27528885
Background: Hepatitis B virus (HBV) X protein (HBx) reported to be associated with pathogenesis of hepatocellular carcinoma (HCC) and miR-122 expression is down regulated in HCC. Previous studies reported miR-122...
4.
Ferraris P, Chandra P, Panigrahi R, Aboulnasr F, Chava S, Kurt R, et al.
Am J Pathol
. 2016 Feb;
186(4):938-51.
PMID: 26896692
The single nucleotide polymorphism located within the IFNL3 (also known as IL28B) promoter is one of the host factors associated with hepatitis C virus (HCV) clearance by interferon (IFN)-α therapy;...
5.
Aboulnasr F, Hazari S, Nayak S, Chandra P, Panigrahi R, Ferraris P, et al.
PLoS One
. 2015 Dec;
10(12):e0141655.
PMID: 26657215
Background: HCV replication in persistently infected cell culture remains resistant to IFN-α/RBV combination treatment, whereas IFN-λ1 induces viral clearance. The antiviral mechanisms by which IFN-λ1 induces sustained HCV clearance have...
6.
7.
Kurt R, Chandra P, Aboulnasr F, Panigrahi R, Ferraris P, Aydin Y, et al.
PLoS One
. 2015 May;
10(5):e0125962.
PMID: 25961570
Background: Hepatic steatosis is a risk factor for both liver disease progression and an impaired response to interferon alpha (IFN-α)-based combination therapy in chronic hepatitis C virus (HCV) infection. Previously,...
8.
Panigrahi R, Sarkar N, Biswas A, Pal A, Saha D, Singh S, et al.
J Clin Exp Hepatol
. 2015 Mar;
4(3):202-8.
PMID: 25755561
Background: TNF-α promoter polymorphism has been known to be a potential predictive factor in patients with HBV infection. We therefore tried to investigate whether the TNF-α promoter polymorphism at position...
9.
Biswas A, Panigrahi R, Pal M, De B, Chakrabarti S, Ghosh M, et al.
J Clin Exp Hepatol
. 2015 Mar;
3(4):281-7.
PMID: 25755515
Background: Interleukin-1β (IL-1β) is an important member of the family of the proinflammatory cytokines that modulate outcome of hepatitis B virus (HBV) infection. Objectives: This study was designed to investigate...
10.
Panigrahi R, Chandra P, Ferraris P, Kurt R, Song K, Garry R, et al.
J Virol
. 2014 Oct;
89(1):626-42.
PMID: 25339775
Unlabelled: Ribavirin (RBV) continues to be an important component of interferon-free hepatitis C treatment regimens, as RBV alone does not inhibit hepatitis C virus (HCV) replication effectively; the reason for...